No Data
No Data
Promising Outlook for Alto Neuroscience With ALTO-300's Phase IIb Success Reinforcing Buy Rating
JonesTrading Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $18
TD Cowen Remains a Buy on Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience Reports Positive Outcomes From Phase IIb Trial of MDD Therapy
Alto Neuroscience Shares Are Trading Higher After the Company Announced Interim Analysis Results From Its Phase 2b Trial of ALTO-300.
Express News | Alto Neuroscience Inc -Topline Results Are Expected in Mid-2026